<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03165240</url>
  </required_header>
  <id_info>
    <org_study_id>1378-0008</org_study_id>
    <secondary_id>2017-000563-32</secondary_id>
    <nct_id>NCT03165240</nct_id>
  </id_info>
  <brief_title>This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 4 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated</brief_title>
  <official_title>Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this current trial is to investigate the safety and tolerability of
      4 oral doses of BI 690517 over 28 days in female and male patients with diabetic nephropathy
      as add-on-therapy to Angiotensin Converting Enzyme inhibitor [ACEi] or Angiotensin-receptor
      blockers [ARB].

      Secondary objective is to evaluate the change from baseline in Urine Albumin-to-Creatinine
      Ratio [UACR].
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with drug related Adverse Events (AEs)</measure>
    <time_frame>Up to 35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in morning void urine</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed Urine Albumin-to-Creatinine Ratio (UACR) measured in daytime (10-hour) urine</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Diabetic Nephropathies</condition>
  <arm_group>
    <arm_group_label>BI 690517 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 690517 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 690517 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 690517 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 690517</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>BI 690517 Dose 1</arm_group_label>
    <arm_group_label>BI 690517 Dose 2</arm_group_label>
    <arm_group_label>BI 690517 Dose 3</arm_group_label>
    <arm_group_label>BI 690517 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent in accordance with ICH-GCP and local
             legislation prior to admission to the trial.

          -  Male or postmenopausal (last menstruation ≥ 2 years ago) patients, or female patients
             who are sterilized by either hysterectomy, bilateral salpingectomy and/or bilateral
             oophorectomy. Male patients with partners of child-bearing potential must be willing
             to use condoms from the time of the first intake of study drug until follow-up.

          -  eGFR (Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula) ≥ 20 and &lt;
             60 ml/min/1.73 m2 at Visit 1 measured by the central laboratory and no planned start
             of renal replacement therapy during the trial.

          -  UACR ≥ 200 and &lt;3500 mg/g in spot urine (midstream urine sample) at Visit 1 measured
             by the central laboratory.

          -  Treatment with either ACEi or ARB, stable dose since ≥ 4 weeks before Visit 1 with no
             planned change of the therapy.

          -  Patients with type 1 or type 2 diabetes mellitus, diagnosed before informed consent
             and treated with insulin, glucagon-like peptide (GLP) 1 agonists and/or oral
             antidiabetic medication. Treatment should have been unchanged (investigator's
             judgment) within 4 weeks before Visit 1 and until randomisation.

          -  Glycated Haemoglobin (HbA1c) ≥ 6.5% and &lt; 10.0% at Visit 1 measured by the central
             laboratory.

          -  Seated SBP ≥ 110 and ≤ 180 mmHg and DBP ≥ 70 and ≤ 110 mmHg at Visit 1

          -  Age at screening ≥ 18 years for male and permanently sterilized female patients and ≥
             45 years for postmenopausal female patients.

          -  Body Mass Index (BMI) ≥ 18.5 and &lt; 45 kg/m2.

        Exclusion Criteria:

          -  Treatment with with SGLT2 inhibitors and/or inhibitors of aldosterone mediated effects
             like mineralocorticoid receptor antagonists at visit 1 and thereafter.

          -  Intake of potassium sparing diuretics like amiloride or potassium supplements during
             the study (this period starts at Visit 1).

          -  At Visit 1 cortisol peak level 30 minutes (± 5 min) after iv injection of ACTH &lt; 500
             nmol/l (180 μg/l).

          -  Dual or triple blockade of the Renin Angiotensin System (RAS) (e.g. ACEi + ARB; ACEi +
             renin inhibitor; or ARB + renin inhibitor; or ACEi + ARB + renin inhibitor) 12 weeks
             before Visit 1 and for the duration of study.

          -  History of non-diabetic renal disease according to investigator's opinion and/or renal
             transplant recipients.

          -  Hyperkalaemia (K+ &gt; 5.0 mmol/L) at visit 1 and until randomization.

          -  Clinical signs of acute or chronic urinary tract infection 14 days before
             randomization (based on investigator's judgement).

          -  Acute febrile diseases 14 days before randomisation (based on investigator´s
             judgement).

          -  Heart failure, patients with NYHA III / IV.

          -  Surgery or trauma with significant blood loss or blood donation within 12 weeks prior
             to first administration of study medication (based on investigator´s judgement) or
             planned surgeries during the trial e.g. hip replacement (based on investigator's
             judgement).

          -  Any other medical condition that in the investigator's opinion poses a safety risk for
             the patient or may interfere with the study objectives.

          -  Any laboratory value more than 3 times above upper limit normal (ULN) at screening
             (visit 1) or any other laboratory value outside the reference range and clinically
             relevant in the investigator's judgment.

          -  Medical history of cancer or treatment for cancer in the last two years prior to Visit
             1 (except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of
             uterine cervix, and prostatic cancer of low grade [T1 or T2] is exempted).

          -  Previous enrolment in this trial.

          -  Currently enrolled in another investigational device or drug study, or less than 30
             days since ending another investigational device or drug study(s), or receiving other
             investigational treatment(s).

          -  Chronic alcohol or drug abuse or any condition that, in the investigator's opinion,
             makes them an unreliable study patient or unlikely to complete the trial.

          -  Women of childbearing potential

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>DK-2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Rossing</last_name>
      <phone>+45 38619705</phone>
      <email>Peter.Rossing@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kolding Sygehus</name>
      <address>
        <city>Kolding</city>
        <zip>DK-6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Winther Rasmussen</last_name>
      <phone>+45 4586523654</phone>
      <email>Ole.Winther.Rasmussen@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>København NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Svendsen</last_name>
      <phone>+45 35312854</phone>
      <email>Ole.Lander.Svendsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, København</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Feldt Rasmussen</last_name>
      <phone>+45 35452135</phone>
      <email>bo.feldt-rasmussen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Nord Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Zaoui</last_name>
      <phone>+33 (0)4 76 76 55 23</phone>
      <email>pzaoui@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronan Roussel</last_name>
      <phone>+33 (0)1 40 25 73 01</phone>
      <email>ronan.roussel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital la Milétrie - CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samy Hadjadj</last_name>
      <phone>+33 (0)5 49 44 40 34</phone>
      <email>samy.hadjadj@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Nord Laënnec</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand Cariou</last_name>
      <phone>+33 (0)2 53 48 27 01</phone>
      <email>bertrand.cariou@univ-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Birkenfeld</last_name>
      <phone>+49 (351) 45813651</phone>
      <email>Andreas.Birkenfeld@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>InnoDiab Forschung GmbH</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Schürholz</last_name>
      <phone>+49 (201) 89942100</phone>
      <email>thomas.schuerholz@innodiab.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inamed GmbH</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bärbel Huber</last_name>
      <phone>+49 (89) 893569533</phone>
      <email>b.huber@inamed-cro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ. Gen. Hosp. of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moses Elisaf</last_name>
      <phone>+302651007509</phone>
      <email>melisaf54@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iatriko of Athens Group/ Iatriko of P. Faliro</name>
      <address>
        <city>P. Faliro</city>
        <zip>17562</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Doupis</last_name>
      <phone>+30 2109892300</phone>
      <email>john.doupis@joslin.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iatriko Psychikou</name>
      <address>
        <city>Psychiko</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerasimos Karousos</last_name>
      <phone>+302106974281</phone>
      <email>gkarousosmd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Thessaloniki AHEPA</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Triantafyllos Didangelos</last_name>
      <phone>00302310994776</phone>
      <email>didang@med.auth.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculty hospital with clinics F.D. Roosevelta</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>97409</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Lackova</last_name>
      <phone>+421 484 412 651</phone>
      <email>lackoe7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Old Town Bratislava University Hosp,</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Caprnda</last_name>
      <phone>+421257290449</phone>
      <email>martin.caprnda@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>D &amp; R s.r.o.</name>
      <address>
        <city>Kosice</city>
        <zip>040 22</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Fedacko</last_name>
      <phone>+421 55 7996395</phone>
      <email>janfedacko@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTC Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Curiac</last_name>
      <phone>+4631 342 96 70</phone>
      <email>dan.curiac@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sjukhuset, Härnösand</name>
      <address>
        <city>Härnösand</city>
        <zip>87182</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staffan Salmonsson</last_name>
      <phone>+46 611-20930</phone>
      <email>staffan.salmonsson@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset, Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olof Hellberg</last_name>
      <phone>0046 19 602 10 00</phone>
      <email>olof.hellberg@regionorebrolan.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Slovakia</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>Norway</country>
  </removed_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

